



Europäisches Patentamt  
European Patent Office  
Office européen des brevets



(11) Publication number:

0 613 899 A2

(12)

## EUROPEAN PATENT APPLICATION

(21) Application number: 93111445.8

(51) Int. Cl. 5: C07D 451/12, C12N 15/06,  
C07K 15/28, C12N 5/18,  
//G01N33/94

(22) Date of filing: 16.07.93

(23) Declaration under Rule 28(4) EPC (expert solution)

The applicant has filed a statement in accordance with Rule 28 (4) EPC (issue of a sample only to an expert). Accession number(s) of the deposit(s): FERM BP-4177.

(30) Priority: 04.03.93 JP 43502/93  
15.03.93 JP 53380/93

(43) Date of publication of application:  
07.09.94 Bulletin 94/36

(84) Designated Contracting States:  
DE FR GB

(71) Applicant: MATSUSHITA ELECTRIC  
INDUSTRIAL Co., Ltd.  
1006-banchi, Oaza-Kadoma  
Kadoma-shi, Osaka (JP)

(72) Inventor: Yugawa, Keiko  
4-36-201, Sengokunishi-machi  
Kadoma-shi, Osaka 571 (JP)  
Inventor: Sigetoh, Nobuyuki  
6-7-2-818, Sekime,  
Joto-ku  
Osaka-shi, Osaka 536 (JP)  
Inventor: Miyazaki, Jinsei  
75-2-704, Kano 2-chome  
Higashiosaka-shi, Osaka 578 (JP)  
Inventor: Mitsumata, Tadayasu  
1-23-30, Yamanoue  
Hirakata-shi, Osaka 573 (JP)

(74) Representative: VOSSIUS & PARTNER  
Postfach 86 07 67  
D-81634 München (DE)

(54) Cocaine derivative, protein conjugate thereof, monoclonal antibody producing cell line, method for preparing the cell line and monoclonal antibody.

(57) A method for preparing a cocaine-protein conjugate easily by using a cocaine derivative having a methoxy carbonyl group and benzoyl group. This conjugate is useful for the detection of cocaine or cocaine derivatives.

A monoclonal antibody, a monoclonal antibody producing cell line, and a method for producing the monoclonal antibody producing cell line by using the above cocaine-protein conjugate as an immunogen is also described. The method of the invention comprises preparing a cocaine-protein conjugate with a pyridyl dithiococaine derivative of Formula (1):

EP 0 613 899 A2

ATTORNEY DOCKET NUMBER: 11662-003-999  
SERIAL NUMBER: 10/647,071

REFERENCE: B01

Rank Xerox (UK) Business Services  
(3.10/3.09/3.3.4)



Europäisches Patentamt  
European Patent Office  
Office européen des brevets



(11) Publication number:

**0 613 899 A2**

(12)

## EUROPEAN PATENT APPLICATION

(21) Application number: 93111445.8

(61) Int. Cl. 5: **C07D 451/12, C12N 15/06,**  
**C07K 15/28, C12N 5/18,**  
**//G01N33/94**

(22) Date of filing: **16.07.93**

(23) Declaration under Rule 28(4) EPC (expert solution)

The applicant has filed a statement in accordance with Rule 28 (4) EPC (issue of a sample only to an expert). Accession number(s) of the deposit(s): FERM BP-4177.

(30) Priority: **04.03.93 JP 43502/93**  
**15.03.93 JP 53380/93**

(43) Date of publication of application:  
**07.09.94 Bulletin 94/36**

(84) Designated Contracting States:  
**DE FR GB**

(71) Applicant: **MATSUSHITA ELECTRIC  
INDUSTRIAL Co., Ltd.**  
**1006-banchi, Oaza-Kadoma**  
**Kadoma-shi, Osaka (JP)**

(72) Inventor: **Yugawa, Keiko**  
**4-36-201, Sengokunishi-machi**  
**Kadoma-shi, Osaka 571 (JP)**  
Inventor: **Sigetoh, Nobuyuki**  
**6-7-2-818, Sekime,**  
**Joto-ku**  
**Osaka-shi, Osaka 536 (JP)**  
Inventor: **Miyazaki, Jinsei**  
**75-2-704, Kano 2-chome**  
**Higashiosaka-shi, Osaka 578 (JP)**  
Inventor: **Mitsumata, Tadayasu**  
**1-23-30, Yamanoue**  
**Hirakata-shi, Osaka 573 (JP)**


(74) Representative: **VOSSIUS & PARTNER**  
**Postfach 86 07 67**  
**D-81634 München (DE)**

(54) **Cocaine derivative, protein conjugate thereof, monoclonal antibody producing cell line, method for preparing the cell line and monoclonal antibody.**

(57) A method for preparing a cocaine-protein conjugate easily by using a cocaine derivative having a methoxy carbonyl group and benzoyl group. This conjugate is useful for the detection of cocaine or cocaine derivatives.

A monoclonal antibody, a monoclonal antibody producing cell line, and a method for producing the monoclonal antibody producing cell line by using the above cocaine-protein conjugate as an immunogen is also described. The method of the invention comprises preparing a cocaine-protein conjugate with a pyridyl dithiococaine derivative of Formula (1):

**EP 0 613 899 A2**



which binds to a protein by a disulfide bond, immunizing A/J mouse with the conjugate, fusing its spleen cell and a myeloma cell line, cloning the fusion to produce a monoclonal antibody producing cell line, culturing the cell line, and purifying a supernatant of the culture to form a monoclonal antibody to specifically bind to cocaine or cocaine derivatives.


The present invention relates to a cocaine-protein conjugate for use as an antigen to produce an anticocaine antibody, a cocaine derivative as a starting material for the conjugate, a novel monoclonal antibody producing cell line obtained from the antigen and a monoclonal antibody produced by the cell line. The monoclonal antibody is useful in immunochemically detecting cocaine or its derivative out of blood or 5 air with high sensitiveness.

J. Pharmacol. Exp. Ther., vol.199, p171 (1976) proposes a synthesis of an anti-cocaine antibody for use in an immunoassay for cocaine, and an antigen necessary in preparing the antibody. The antibody reported is, however, a polyclonal antibody which can be obtained from refined blood of a goat or rabbit immunized using an antigen of ecgonine of Formula (1).

10

15

20



To obtain an anti-cocaine antibody highly specific for cocaine, a cocaine-protein conjugate must be 25 formed by using a derivative keeping the cocaine framework as precise as possible. Unfortunately, ecgonine lacks a methoxycarbonyl group and benzoyl group each characteristic of the cocaine molecule.

The polyclonal antibodies of the prior art can simply be prepared; on the other hand, it is less reproducible because the properties of the product depend on every individual of the experimental animals. Thus, it is quite difficult to provide antibodies of the same quality.

30 Polyclonal antibodies are a mixture of a diversity of antibodies having respective affinity. All the affinities they have prevent us using polyclonal antibody in a sensitive detection system because of their low affinity for a molecule of interest. In accordance with the above paper, we tried to obtain a monoclonal antibody of much affinity for cocaine; however, we could not succeed because ecgonine as an antigen is too different in structure from cocaine.

35

#### SUMMARY OF THE INVENTION

The invention aims to provide a method for easily preparing a cocaine-protein conjugate based on cocaine characterized by a methoxycarbonyl group and a benzoyl group.

40 The invention further aims to provide a monoclonal antibody of high affinity for cocaine or cocaine derivatives by immunizing with the cocaine-protein conjugate.


The invention further aims to provide a cell line for producing the monoclonal antibody.

To attain the above-mentioned aims, the inventors brought about an amino derivative of cocaine based 45 on norcocaine substituted with an amino alkyl group in its secondary amino group, a pyridyl dithio derivative of an amino cocaine derivative substituted with a 3-(2-pyridyl dithio)propynoyl group in its amino group, and a cocaine-protein conjugate. Further, the inventors established a monoclonal antibody producing cell line by fusing a spleen cell derived from mouse immunized with an antigenic cocaine-protein conjugate and a cell line derived from a myeloma cell culture and cloning the fusion.


A first compound of the invention is shown in Formula (2):

50

55



15 wherein n is an integer of 1 or more and Ph is a benzene ring.  
 A first cocaine-protein conjugate is the above cocaine derivative conjugated to a protein.  
 A second compound of the invention is shown in Formula (3):



35 wherein n is an integer of 1 or more and Ph is a benzene ring.  
 A second cocaine-protein conjugate is the second cocaine derivative conjugated to a protein by a disulfide bond.  
 The method for preparing a monoclonal antibody producing cell line comprises fusing a spleen cell derived from a mouse immunized with an antigen of the first cocaine-protein conjugate and a cell line derived from a myeloma cell line and cloning the fusion.  
 It is preferable in the above method that the protein is keyhole limpet hemocyanin.  
 It is also preferable in the above method that the cell line derived from a myeloma cell line is P3X63-Ag8.653.  
 It is also preferable in the above method that the mouse is derived from an A/J strain.  
 The cell line of the invention is preferably a monoclonal antibody producing cell line deposited in Fermentation Research Institute Agency of Industrial Science and Technology, Japanese Ministry of Industrial Trade and Industry as No.BP-4177 produced with the above method, characterized by producing an antibody capable of specifically binding to cocaine or cocaine derivatives.  
 The invention further aims to provide a monoclonal antibody from the above monoclonal producing cell line.  
 With the amino derivatives of cocaine of the invention, one can readily prepare a pyridyl dithio derivative of an amino cocaine derivative having a disulfide group capable of linking to a protein, keeping the cocaine framework as it is. By immunizing a test animal with a cocaine-protein conjugate made from the above pyridyl dithio derivative, one can get a cell line for producing an antibody of higher affinity for cocaine because the cocaine-protein conjugate holds the cocaine framework.  
 After immunoreaction, antibody-producing cells are stored in spleen. Although a spleen is unable to reproduce by itself, it can proliferate and produce a hybridoma cell line by fusing with a cell line derived from myeloma. The hybridoma cell line vigorously produces antibodies as it proliferates. By selecting a

hybridoma cell which has much multiplication ability and produces an antibody having the highest affinity for a certain molecule and cloning the hybridoma, one can procure a desired monoclonal antibody. The monoclonal antibody thus obtained is a single kind of antibody, and of high-affinity. A constant quality of monoclonal antibody can permanently be provided by culturing the hybridoma.

5 FIGURE 1 is a graph showing the binding ability of a monoclonal antibody for an antigen in solid phase with an ELISA assay in an embodiment of the invention;  
 FIGURE 2 is a graph showing results of detecting cocaine with the ELISA method using a monoclonal antibody of an example of the invention.

In the preferred embodiments of the invention, an amino derivative of cocaine is obtained from 10 norcocaine and an amino group. The amino group is, for example,  $X(CH_2)_nR$  where X is a halogen, n is an integer of 1 or more, and R is succinimidyl or male imidyl or futa imidyl.

A pyridyl dithio derivative of cocaine is obtained by introducing a 3-(2-pyridylthio)propynoyl group to the above amino derivative.

What protein is suitable as a carrier depends on both the test animal and the antigen. Our experiments 15 using a variety of proteins such as chicken-gamma-globulin, bovine serum globulin, or keyhole limpet hemocyanine revealed that keyhole limpet hemocyanin (hereinafter abbreviated as KLH) was the possible best carrier protein in the practice of the invention.

To obtain a cell line producing a monoclonal antibody of high affinity, one needs to attain antisera of high antibody titer. Such an immune response depends on the kind and strain of the experimental animals.

20 The inventors immunized different kinds of mice such as A/J, BALB/c, DBA/2, C57BL/6, C3H/He and found that an A/J mouse was the best candidate to produce an antiserum with the highest titer.


Finally, the proliferation ability of a hybridoma depends largely on the kind of cell line derived from the mouse myeloma in the cell fusion. Our experiments using a cell line derived from a diverse of mice revealed that a cell line of P3X63-Ag8.653 makes a hybridoma proliferate at the possible best speed.

25 The embodiments of the invention will be hereinafter be explained with reference to a cocaine derivative, a 2-pyridyl dithio derivative of cocaine, a cocaine-protein conjugate, a method for producing monoclonal antibody producing cell line, a monoclonal antibody, and finally detection of cocaine therewith.

#### Example 1

30 A method for preparing an amino derivative of cocaine will be explained with reference to an example using an aminobutyl group. Firstly, norcocaine was prepared from cocaine. Then, the norcocaine was subjected to react with butyl phthalimide to form the object amino derivative.


(A) Preparation of norcocaine  
 35 Norcocaine of Formula (4) was prepared as follows.  
 Cocaine (500 mg) was dissolved in a mixture (21 ml) of acetonitrile and water (1:2). Acetic acid (0.5 ml) was added to the solution to adjust its pH to approximately 5. To the solution was added dropwise 21ml aqueous potassium permanganate ( $KMn_4O = 534$  mg, 3.78 mmol, 2.05 eq.) over 3 hours. The solution was stirred overnight at room temperature. After removing the resulting precipitate by filtration, 40 potassium carbonate (1050 mg) was added to the filtrate to adjust its pH to approximately 8. The filtrate was extracted with ether three times and dried over anhydrous sodium sulfate overnight. The sodium sulfate was removed out of the extract and ether was distilled off under reduced pressure to give colorless liquid. The liquid was purified by silica-gel thin layer chromatography (hereinafter abbreviated as TLC) using as an eluent ammonia saturated chloroform to give norcocaine (269 mg) of Formula (4):



Yield: 56%

Then, norcocaine was subjected to react with butyl phthalimide to form an object amino derivative.  
 (B) Introduction of butyl phthalimide to norcocaine


The butyl phthalimide derivative of norcocaine of Formula (5) was prepared as follows.  
 5 Norcocaine (268 mg, 0.93 mmol), bromo butylphthalimide (314 mg, 1.11 mmol, 1.2 eq.) and anhydrous sodium carbonate (147 mg, 1.39 mmol, 1.5 eq.) were dissolved in benzene(10 ml) and the mixture was refluxed under nitrogen atmosphere for 72 hours. After cooling to room temperature, the solution was filtered. The filtrate was extracted with 1N hydrochloric acid three times, and the aqueous layer was extracted with chloform three times. The extract was dried over anhydrous sodium sulfate, and chloroform was distilled off under reduced pressure to give colorless crystal. The crystal was purified by TLC (eluent: ammonia saturated chloform/benzene = 1/3) to give a butyl phthalimide derivative (270 mg) of Formula (5):  
 10  
 15  
 20  
 25  
 30



Yield: 60%

35 (3) Preparation of an amino derivative

The amino derivative of Formula (6) was prepared as follows.  
 Butyl phthalimide derivative of Formula (5) (100 mg, 0.20 mmol) was dissolved in 95% ethanol (3 ml), to which hydrazine hydrate (0.20 mmol) was added before a 2-hour reflux. The reaction mixture was purified 40 by TLC (eluent: ammonia saturated chloform/methanol = 10/1) to give an amino derivative (57 mg) of Formula (6):  
 45  
 50



55

Yield: 78%


Referring to an amino group, bromo alkylphthalimide was used for preparation of the amino derivative in

the above embodiment; besides, other amino groups containing an amino alkyl group were also usable.

Example 2

5 The 2-pyridyl dithio derivative of cocaine of Formula (7) was prepared as follows.

The above amino derivative (84 mg, 0.23 mmol) prepared as in Example 1 was dissolved in ethanol (1 ml). To the solution was added dropwise a solution of o-succinimidyl-3-(2-pyridyl-dithio)-1-propionate (hereinafter abbreviated as SPDP (73 mg, 0.23 mmol) in ethanol (1 ml). After stirring at room temperature for 1 hour, the solution was purified by TLC (eluent:ammonia saturated chloform) to give a 2-pyridyl dithio 10 derivative (133 mg) of Formula (7) :



Yield: 100%

In the above embodiment, the starting material was an amino butyl derivative. Instead of that, other 30 amino alkyl derivatives were usable as well.

In the above embodiment, SPDP was used to introduce a pyridyl dithio group to the amino cocaine derivative. Instead of SPDP, other compounds were usable as well as long as they contain a 3-(2-pyridyl-dithio)propynoyl group.

35 Example 3

A method for preparing a cocaine-protein conjugate will be explained with reference to an example using KLH.

Firstly a complex of KLH and SPDP (hereinafter abbreviated as KLH-SPDP) was prepared. Then a 40 cocaine-KLH conjugate was produced.

(A) Preparation of KLH-SPDP

KLH (200 mg) was dissolved in 30ml phosphate buffer saline (hereinafter abbreviated as PBS). To the solution was added dropwise 0.5ml SPDP (9.4 mg, 15 eq.) in ethanol while stirring at room temperature for 30 minutes. The resulting precipitate was removed by a 10min centrifugation at 20000 rpm. The obtained supernatant was subjected to gel filtration chromatography using a 2 x 80 cm Sephadex G25 column (Pharmacia Fine Chemicals) to give a solution of KLH-SPDP in PBS (40 ml). The number of SPDP binding to a KLH molecule was determined as follows.

Out of the solution of KLH-SPDP in PBS thus obtained, a volume of 1ml was used to measure absorbance at 280 nm. The absorbance ( $A_{280}$ ) was 3.6005. To the solution was added 50  $\mu$ l of 100mM aqueous dithiothreitol solution (hereinafter abbreviated as DTT). After 5 minutes, the solution was used to measure absorbance at 343 nm. The absorbance ( $A_{343}$ ) was 1.576. The concentration of pyridin-2-thione was calculated as shown in Formula (8), provided that  $1.12 \times 10^5$  was a 343nm molecular absorption coefficient of the pyridin-2-thione released from the DTT reduction.

55  $[ \text{pyridin-2-thione} ] = 1.576 / 1.12 \times 10^5 = 1.9505 \times 10^{-4} (\text{M}) \quad \text{Formula (8)}$

Hereinafter, a compound name in brackets means a molar concentration of the compound. The concentration is equivalent to that of SPDP introduced to KLH.

Besides, the 2-pyridyl sulfide group in SPDP contributes largely to  $A_{280}$  so that the following correction is needed to calculate the concentration of KLH.  $A_{280\text{ KLH}}$  depending on KLH is calculated as follows:

5  $A_{280\text{ KLH}} = 3.6005 - (1.9505 \times 10^{-4} \times 5.1 \times 10^3) = 2.6057$ ,

provided that  $5.1 \times 10^3$  was a 280nm molecular absorption coefficient of the 2-pyridyl-disulfide group. Consequently, the KLH concentration and the number of SPDP molecules introduced to a KLH molecule are calculated in accordance with Formula (9):

10  $[KLH] = 2.6057 / 1.12 \times 10^{-5} = 2.3265 \times 10^{-5} \text{ M}$ ;  $[SPDP]/[KLH] = 1.9505 \times 10^{-4} / 2.3265 \times 10^{-5} = 8.3$  Formula (9)

15 (B) Preparation of a cocaine-KLH conjugate

A cocaine-KLH conjugate was prepared as follows.

20 DTT (77.1 mg, 50 eq.) was added to 40ml KLH-SPDP/PBS solution ( $2.3265 \times 10^{-5} \text{ M}$ ), followed by stirring at room temperature for 30 minutes. After removing the resulting precipitate by a 10min centrifugation at 20000 rpm, the obtained supernatant was subjected to gel filtration chromatography using a  $2 \times 80 \text{ cm}$  Sephadex G25 column (Pharmacia Fine Chemicals) to give 48ml KLH-SPDP (SH free)/PBS solution ( $1.7316 \times 10^{-5} \text{ M}$ ). To the given solution was added 4.63 mg ( $8.312 \times 10^{-3} \text{ mmol}$ ) of the pyridyl dithio derivative of Formula (7), followed by stirring at  $4^\circ\text{C}$  overnight. After removing the resulting precipitate by a 10min centrifugation at 20000 rpm, the obtained supernatant was used to measure absorbance at 343nm ( $A_{343}$ ). The absorbance was 1.0352.

25 The obtained supernatant was subjected to gel filtration chromatography using a  $2 \times 80 \text{ cm}$  Sephadex G25 column (Pharmacia Fine Chemicals) to give 48ml cocaine-KLH/PBS solution.

The number of the pyridyl dithio derivative binding to a KLH molecule was determined as follows. The fact that  $A_{343}$  just after reaction was 1.0352 and that  $8.08 \times 10^{-3}$  was a 343nm molecular absorption coefficient of pyridin-2-thione released induced that a concentration of pyridin-2-thione was calculated as shown in Formula (10):

30  $[\text{pyridin-2-thione}] = 1.0352 / 8.08 \times 10^3 = 1.2812 \times 10^{-4} \text{ M}$  Formula (10)

The concentration is equivalent to that of the pyridyl dithio derivative introduced to KLH.

35 Because the KLH concentration was  $1.7316 \times 10^{-5} \text{ M}$ , the number of pyridyl dithio derivative molecules introduced to a KLH molecule is calculated in accordance with Formula (11):

30  $[\text{pyridyl dithio derivative}]/[KLH] = 1.2812 \times 10^{-4} / 1.7316 \times 10^{-5} = 7.4$  Formula (11)

40 This indicates that in a cocaine-KLH conjugate 7.4 molecules of cocaine bind to a KLH molecule.

In the above embodiment, an antigen was prepared using KLH as a protein. In accordance with the present invention, an immunogen for the preparation of a monoclonal antibody producing cell line can similarly be prepared using other carrier proteins such as bovine serum albumin or chicken-gamma-globulin instead of KLH.

45 Example 4

Production of a monoclonal antibody producing cell line and a monoclonal antibody

50 A method for producing a monoclonal antibody producing cell line and a monoclonal antibody will be explained one by one with reference to the following embodiments.

(A) Preparation of adjuvant emulsion

55 The cocaine-KLH conjugate (hereinafter abbreviated as CC-KLH), which was obtained by a series of processes in Examples 1, 2 and 3, was diluted with PBS to adjust its concentration to 1 mg/ml. Out of an adjuvant (Freund's complete adjuvant containing heat killed and dried *Mycobacterium tuberculosis*, Wako Pure Chemical Industries, Ltd., H37Rv), 6ml volume was taken while stirring vigorously. To the adjuvant was added gradually 6ml CC-KLH solution in three times while stirring with a homogenizer (10000 rpm) to emulsify until a few drops of water did not spread on the solution any more.

## (B) Immunization of mouse

Every 100  $\mu$ l of the prepared adjuvant emulsion containing CC-KLH was injected intraperitoneally to each of ten 8-week-old mice (A/J).

## (C) Recognition of antibody production

5 After 70 days since the immunogenic injection, 50 to 100  $\mu$ l blood out of immunized mouse from ophthalmic veins was sampled into a centrifugal tube. Serum was isolated by centrifugation, and ELISA screening revealed that every mouse produced an anti-cocaine antibody.

## (D) Booster shot to mouse

10 A booster shot (supplementary weak immunogenic injection) was given to two mice to enlarge their spleen.

The two mice showed higher reactivity than any other mice in the above screening. Adjuvant-free CC-KLH solution (1 mg/ml) diluted with PBS was used as an immunogen. This immunogen (100  $\mu$ l) was injected intraperitoneally to the two mice after 71 days since the immunogenic injection.

## (E) Cell fusion

15 A spleen cell was taken out of the mice after 3 days since the booster shot. The cell was fused with a cell line (P3X63-Ag8.653) derived from a mouse myeloma by a conventional way using polyethylene glycol of an average molecular weight 1500. A spleen cell from the same mice as the feeder (growth factor producing cell) was cultured on two 96-well plates each containing HAT medium with 15wt% fetal calf serum (hereinafter abbreviated as FCS). A week later, HAT medium was replaced with HT medium containing 15wt% FCS.

## (F) Cloning

20 ELISA screening was carried out to select 12 wells showing the highest antibody titer out of all the wells. All the liquid in the selected 12 wells were collected and diluted with a medium containing 15wt% FCS to a concentration of a single cell per well (limiting dilution). It was equally divided to 12 sheets of 96-well microplates. To accelerate initial proliferation, thymus gland cell of a 5-week-old mouse (Balb/c) was used as a feeder cell. After every culture using different size of plates, 24-well and 6-well plates, ELISA screening for serum was repeated to pick up a cell line which could exhibit higher antibody titer for cocaine and multiply well. The final concentration of the cell culture was  $5 \times 10^5$  cells/ml.

25 (G) After removing the supernatant, the finally selected cell line in a concentration of  $5 \times 10^6$  cells/ml was floated in a solution of FCS and dimethylsulfoxide (9:1) and freezed at -80 °C. The freezed cell line was then kept at -135 °C for future use.

30 (H) Monoclonal antibodies were purified by affinity chromatography using a protein A binding gel (protein A Sepharose, CL-4B, Pharmacia) from the supernatant of cell culture. SDS polyacrylamide gel electrophoresis revealed that the purified monoclonal antibody was IgG consisting of the Heavy chain (approximately 50000 molecular weight) and the Light chain (approximately 20000 molecular weight) compared with protein standards.

35 In the above embodiment, KLH was used as a protein to bind cocaine with. In accordance with the present invention, a monoclonal antibody producing cell line can similarly be produced using other carrier proteins such as bovine serum albumin or chicken-gamma-globulin instead of KLH.

40 Example 5

## Detection by ELISA

45 Evaluation of the antiserum obtained by the processes as in Example 4 and culture supernatant, and detection of cocaine or cocaine derivatives were performed by an ELISA assay using the monoclonal antibody.

## (A) Antigen coating

50 An antigenic solution of BSA in a concentration of 0.1 mg/ml was prepared by diluting with PBS containing 0.4wt% sodium azide, a conjugate prepared in the way similar to CC-KLH preparation where a cocaine molecule binds to a BSA molecule in a ratio of 1:1. This solution will be abbreviated as BSA-PBS-Az. The antigenic solution was equally placed into a 96well vinyl-chloride microplate (Coster) in a concentration of 100  $\mu$ l/well. The microplate was allowed to stand at 20 °C overnight.

55 After antigenic solution was removed with an aspirator, the plate was washed three times with PBS, which was then removed completely with an aspirator.

## (B) Blocking

BSA-PBS-Az solution was placed into the plate in a concentration of 250  $\mu$ l/well. The microplate was allowed to stand at room temperature for 30 minutes before removing BSA-PBS-Az with an

aspirator. Unless the plate was used that day, the plate was preserved on a wet filter paper in an airtight container at 4 °C for future use.

(C) Reaction of the antibody

5 Antibody solutions such as antiserum, culture supernatant, or purified antibody, each of which was diluted in different concentrations with a BSA-PBS-Az solution, were placed into the above plate in a concentration of 100  $\mu$ l/well. Inhibition solution (50  $\mu$ l/well), i.e., cocaine, norcocaine, ecgonine, methylecgonine, and benzoylecgonine solutions, was placed into the plate, followed by addition of the antigenic solution (50  $\mu$ l/well) while shaking. The plate was kept at room temperature for 3 hours. Then, the antigenic solution was removed with an aspirator and the plate was washed three times with PBS, which was then removed completely with an aspirator.

10 (D) Secondary antibody reaction

15 A secondary antibody solution of 0.2  $\mu$ g/ml peroxidase-labelled goat antimouse IgG (KLP, Cat. 141806 lot. HL10-5) in PBS containing 1 wt% BSA was placed into the plate in a ratio of 50  $\mu$ l/well. The plate was allowed to stand at room temperature for 30 minutes. Then, the secondary antigenic solution was removed with an aspirator and the plate was washed three times with PBS, which was then removed completely with an aspirator.

20 (E) Termination of substrate reaction

25  $\alpha$ -Phenylene diamine for biochemical use (40 mg) was dissolved in 10ml citric acid-phosphate buffer (pH=5). To the solution was added a substrate solution of 30wt% aqueous hydrogen peroxide (4  $\mu$ l) to a concentration of 100  $\mu$ l/well, and the mixture was allowed to stand at room temperature for 10 minutes. Then, the reaction was terminated with 4N sulfuric acid in a concentration of 25  $\mu$ l/well.

20 (F) Measurement

25 The absorbance at more than 492 nm was measured using a TOYOSODA MICRO PLATE READER. A reference value was usually given in a first row of wells each containing purified water. A control value of absorbance for the wells going through no (c) process was used appropriately.

30 Figure 1 shows the binding ability between each concentration of a monoclonal antibody solution and CC-BSA as a solid phase antigen coating the plate. Vertical and horizontal lines in Figure 1 show the absorbance and the logarithm of the antibody concentration mole/l (hereinafter referred to as M), respectively.

35 As Figure 1 indicates, the binding is saturated in a concentration of more than  $10^{-9}$  M; that is, inhibition value at  $10^{-9}$  M cocaine is zero or more.

35 Next, the detection for each concentration of cocaine using  $10^{-9}$  M antibody is shown in Figure 2. Vertical and horizontal lines in Figure 2 show the inhibition (%) and the logarithm of the cocaine concentration (M), respectively.

35 Inhibition (%) was calculated as follows:

$$\text{Inhibition (\%)} = (1 - \text{OD}_x / \text{OD}_{\text{max}}) \times 100$$

40  $\text{OD}_x$  : Absorbance at xM cocaine

$\text{OD}_{\text{max}}$  : Absorbance at 0M cocaine

45 With this detection method, an increase in cocaine concentration results in a decrease in absorbance. Thus, inhibition as shown above will rise together with cocaine concentration.

As shown in Figure 2,  $10^{-9.0}$  M cocaine was detected under these conditions.

50 Incidentally, the monoclonal antibody seems to have fairly affinity for structurally related substances of the corresponding immunogen. Cocaine derivatives will be detected with a monoclonal antibody produced by the immunomethodology using CC-KLH though that detectability was rather reduced.

55 Here are presented relative sensitivities for cocaine and its derivatives in the same way as referred to above.

norcocaine	10
ecgonine	13
methylecgonine	20
benzoylecgonine	30


55 The term relative sensitivity means the lowest detectable concentration ratio of every substance to that of cocaine. A higher figure means lower detectability.

As explained above, the invention provides a cocaine-protein conjugate having methoxy carbonyl and benzoyl groups both characteristic of cocaine from an amino derivative of norcocaine substituted with an amino alkyl group in its secondary amino group, and a pyridyl dithio derivative of the above amino derivative substituted with 2-pyridyl dithio propynoyl group in its amino group.

5 Further, the invention provides a monoclonal antibody with high affinity for cocaine or cocaine derivatives and a monoclonal antibody producing cell line.


**Claims**

10 1. An amino derivative of cocaine of Formula A



wherein n is an integer of 1 or more and Ph is a benzene ring.

30 2. A pyridyl dithio derivative of an amino cocaine derivative of Formula B



wherein n is an integer of 1 or more and Ph is a benzene ring.

50 3. The cocaine derivative of claim 1, conjugated to a protein.

4. The cocaine derivative of claim 2, conjugated to a protein by a disulfide bond.

5. A method for preparing a monoclonal antibody producing cell line, comprising fusing a spleen cell derived from a mouse immunized with an antigen comprising the cocaine derivative conjugated to a protein of claim 3 and a cell line derived from a myeloma cell and cloning the fusion.

55 6. The method of claim 5, characterized in that said protein is keyhole limpet hemocyanin.

7. The method of claim 5, characterized in that said cell line derived from a myeloma cell line is P3X63-Ag8.653.
8. The method of claim 5, characterized in that said mouse derives from an A/J strain.
- 5 9. A monoclonal antibody producing cell line producing a monoclonal antibody directed against cocaine or a derivative thereof.
- 10 10. A monoclonal antibody producing cell line producing a monoclonal antibody directed against the protein conjugated cocaine derivative of claim 3 or 4.
11. A monoclonal antibody producing cell line produced with the method of claim 5, being deposited in Fermentation Research Institute Agency of Industrial Science and Technology, Japanese Ministry of Industrial Trade and Industry as No.BP-4177, characterized by producing an antibody capable of 15 specifically binding to cocaine or a cocaine derivative.
12. A monoclonal antibody directed against cocaine or its derivatives.
13. A monoclonal antibody directed against the protein conjugated cocaine derivative of claim 3 or 4.
- 20 14. A monoclonal antibody produced by the monoclonal antibody producing cell line of claim 11.

25

30

35

40

45

50

55

FIG. 1





FIG. 2



**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

**BLACK BORDERS**

**IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**

**FADED TEXT OR DRAWING**

**BLURRED OR ILLEGIBLE TEXT OR DRAWING**

**SKEWED/SLANTED IMAGES**

**COLOR OR BLACK AND WHITE PHOTOGRAPHS**

**GRAY SCALE DOCUMENTS**

**LINES OR MARKS ON ORIGINAL DOCUMENT**

**REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**

**OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**